normative

Blocking Pharma M&A Would Harm Patients

Policies that stop large pharma from buying small biotechs would slow drugs to patients, create inefficient duplication of sales reps calling on the same doctors, and deny investors exits needed to recycle capital into new innovation.

normativepending

Speaker

Rod

Evidence Quote

“if you don't allow M&A of smaller biotech companies happen, a lot of bad things happen. Drugs get to patients slower.”

Source

RTW: Investing Across Healthcare— Business Breakdowns
Created: 11/13/2026, 1:54:32 PM

Your notes

Loading notes...